Natural History of Photoreceptor Degeneration Related to USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Inherited retinal diseases (IRDs) are a group of degenerative disorders that cause progressive vision loss. Retinitis pigmentosa (RP) is the most common form, with a global prevalence of approximately 1 in 4,500. About 20-30% of these cases are syndromic, most notably Usher syndrome (USH), which combines hearing loss with visual impairment. Usher syndrome type 1 (USH1), the most severe form, presents at birth with profound sensorineural hearing loss, vestibular areflexia, and early-onset retinal degeneration. Biallelic mutations in the MYO7A gene, which define the USH1B subtype, account for 70% of USH1 cases. There is currently no treatment available for this serious condition. The objective of the study is to characterize the natural history of retinal degeneration in USH1B patients and to validate functional vision tests using virtual reality and patient-reported outcome questionnaires.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 75
Healthy Volunteers: f
View:

• Be at least 3 years old;

• Have a clinical diagnosis of USH1 in both eyes, meaning subjects with congenital profound deafness, vestibular dysfunction, and rod dystrophy, carrying biallelic class 4 or 5 variants in the MYO7A gene;

• Be affiliated with or beneficiary of a social security system (according to article L1121-8-1 of the French Public Health Code);

⁃ For participants in the MOST-VR mobility test and VR-ViSA visual search test (Streetlab), additional criteria apply:

• Sufficient knowledge of spoken and signed French to ensure understanding of tasks and instructions;

• Have a cochlear implant allowing comprehension of auditory instructions for the virtual reality mobility test and a MMSE score ≥ 20/25;

• Age between 18 and 75 years.

Locations
Other Locations
France
Centre National d'Ophtalmologie des Quinze-Vingts
RECRUITING
Paris
Contact Information
Primary
Odile Cruveiller
ocruveiller@15-20.fr
+33612019825
Backup
Beata Monfort, PhD
recherche@15-20.fr
+33140021738
Time Frame
Start Date: 2025-10-13
Estimated Completion Date: 2032-09
Participants
Target number of participants: 60
Treatments
Pediatric Cohort 1
3-5 years old
Pediatric Cohort 2
6-13 years old
Adult Cohort
14-75 years old
Sponsors
Leads: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

This content was sourced from clinicaltrials.gov